stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) Free cash flow
Legend Biotech Corporation Sponsored ADR's free cash flow for fiscal 2025 was −$128.8M, compared with −$158.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$121.8M. Over the past ten years it has ranged from −$416.0M (fiscal 2023) to $286.7M (fiscal 2018); the current reading is higher than 67% of that period. Legend Biotech Corporation Sponsored ADR ranks 475th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$128.8M | — |
| FY2024 | −$158.1M | — |
| FY2023 | −$416.0M | — |
| FY2022 | −$223.6M | — |
| FY2021 | −$243.9M | — |
| FY2020 | −$272.8M | — |
| FY2019 | −$122.2M | — |
| FY2018 | $286.7M | — |
| FY2017 | −$2.4M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$28.4M | — |
| Mar 2026 | −$92.6M | — |
| Dec 2025 | −$24.6M | — |
| Sep 2025 | $23.8M | — |
| 24 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $85.3M |
| LEGN Legend Biotech Corporation Sponsored ADR | −$121.8M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$202.3M |
| RLAY Relay Therapeutics, Inc. compare | −$214.0M |
| ERAS Erasca, Inc. compare | −$252.1M |
| COGT Cogent Biosciences, Inc. compare | −$309.2M |
| CRSP CRISPR Therapeutics AG compare | −$376.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement